David Johnson (GigaGen, Inc

David Johnson (GigaGen, Inc..) will present ClonAlysis, a cloud-based web portal for the storage and analysis of NGS immune repertoire data. over the past 25 years. strong class=”kwd-title” Keywords: antibody-drug conjugate, antibody engineering, bispecific antibody, effector functions, immunocytokine In this meeting preview, workshop and session chairs share their thoughts on what conference participants may learn in sessions on: accelerating antibody drugs to the clinic; advances in precision targeting; immunocytokine engineering; targeting difficult antigens; Eniporide hydrochloride high-quality research antibodies against the proteome; why choosing targets for bispecific antibodies is so difficult; antibody-based therapeutics for diabesity; emerging targets and new approaches illustrated via preclinical and clinical case studies; antibody effector functions; new targets and applications in immune checkpoint inhibitors; engineering antibody developability; emerging clinical data with therapeutic antibodies and antibody-drug conjugates; next generation sequencing, data analysis, storage and sharing of antibody repertoires; antibodies with enhanced or multiple functionalities; and antibody therapeutics for non-cancer indications. In addition, meeting participants will get a glimpse of the future at The Antibody Society’s Special Session on Antibodies to watch in 2015. Sunday, December 7, 2014 Preconference workshop A: The nuts and bolts of antibody development: Accelerating antibody drugs to the clinic. Co-chairs: James Larrick (Panorama Research Institute and Velocity Pharmaceutical Development LLC) and Mark Alfenito (EnGen Bio, Inc.) The Silver Anniversary Antibody Engineering & Therapeutics meeting will be kicked off with a dynamic, audience-participatory workshop on antibody drug development Rabbit polyclonal to Fyn.Fyn a tyrosine kinase of the Src family.Implicated in the control of cell growth.Plays a role in the regulation of intracellular calcium levels.Required in brain development and mature brain function with important roles in the regulation of axon growth, axon guidance, and neurite extension.Blocks axon outgrowth and attraction induced by NTN1 by phosphorylating its receptor DDC.Associates with the p85 subunit of phosphatidylinositol 3-kinase and interacts with the fyn-binding protein.Three alternatively spliced isoforms have been described.Isoform 2 shows a greater ability to mobilize cytoplasmic calcium than isoform 1.Induced expression aids in cellular transformation and xenograft metastasis. chaired by veterans Jim Larrick (Panorama Research Institute and Velocity Pharmaceutical Development LLC) and Mark Alfenito (EnGen Bio, Inc.). Following Eniporide hydrochloride Dr. Larrick’s introductory remarks regarding an investor’s perspective on therapeutic antibody drugs, Max Vasquez (Adimab) will describe state-of-the-art bioinformatic and in silico methods to facilitate preclinical antibody development. Akbar Nayeem (Molecular Discovery Technologies) will expand on this topic describing computational methods to optimize the structure of clinical candidate antibodies. Next, Nicola Beaucamp (Roche Innovation Center Penzberg) will describe Roche’s integrated approach to Chinese hamster ovary (CHO) cell line selection, upstream process, downstream process and analytics to deliver high-quality bispecific antibodies. Following a break, the workshop will conclude with 2 case studies. The first, by Dorina Saro (Johnson & Johnson), on the development of analytical and biophysical tools to select bispecific monoclonal antibody (mAb) candidates will focus on product develop-ability, and the second, by Thi-Sau Migone (Igenica Biotherapeutics), will cover proteomic-based discovery of a novel hematologic cancer target and IND-enabling studies of a site-specific antibody-drug conjugate (ADC). We anticipate an exciting and informative workshop. Preconference workshop B: Advances in precision targeting Chair: Paul WHI Parren (Genmab) Precise targeting by biopharmaceuticals remains a major challenge in almost all therapeutic areas. This workshop brings together a number of experts who will present recent Eniporide hydrochloride key knowledge-based advances to Eniporide hydrochloride optimize target binding for increased specific activity. Extensive audience participation and discussion will be encouraged. Juergen Schanzer (Roche Innovation Center Penzberg) discusses XGFR, a novel glycoengineered bispecific antibody scaffold targeting EGFR and IGF-1R that combines potent signaling inhibition and antibody-dependent cell-mediated cytotoxicity (ADCC), demonstrating improved targeting properties compared with tetravalent bispecific formats. Christopher Thanos (Halozyme Therapeutics) and Sanjay Khare (ImmunGene, Inc.) will discuss advances in ADC targeting to improve therapeutic index. Dr. Thanos engineered an EGFR antibody for increased tumor specificity, leading to activity against KRAS/BRAF-mutated tumors in vivo. Dr. Khare demonstrates selective targeting of an interferon (IFN) payload with reduced systemic toxicity. After the break, Davide Corti (Humabs Biomed SA) will turn our attention to infectious disease, in which escape from Eniporide hydrochloride antibody targeting remains a critical topic. Dr. Corti shows studies for a number of antibodies derived from human infection that employ various antiviral mechanisms to allow for extraordinary breadth in activity against a range of virus subtypes and subfamilies. Rudolf Kerschbaumer (Baxter Innovations GmbH) will discuss novel data on the well-known pleiotropic proinflammatory cytokine macrophage migration inhibitory factor (MIF). Using phage-display, Dr. Kerschbaumer isolated antibodies that target oxidized MIF (ox-MIF), a previously unrecognized disease-related variant of the cytokine with interesting activity against cancer-associated inflammation and in vivo tumor growth inhibition. Finally, Yuki Iwayanagi (Chugai Pharmaceutical Co, Ltd) will complete the session by discussing a novel approach to enhance the clearance of soluble antigens by making use of engineered antibodies that combine pH-dependent binding activity with enhanced selectivity for the IgG Fc receptor FcRIIb. Overall, the session highlights a number of novel insights and important advances in the selection or engineering of antibodies that, through better precision, bear great promise for the development of improved immunotherapies. Monday, December 8, 2014 Keynote presentations Chair: James D. Marks (University of California, San Francisco; San Francisco General Hospital) The meeting will open with keynote presentations by five luminaries in the field of molecular therapeutics development. Douglas A. Lauffenburger (Massachusetts Institute of Technology) will discuss systems analysis of cell communication network dynamics for therapeutic biologics design. The critical contemporary issue for molecular therapeutics, including biologics, is efficacy. Although the targets.